.jpg "H.C. Wainwright Thinks Onconova Therapeutics")
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Onconova Therapeutics (NASDAQ: ONTX), with a price target of $3. The company’s shares opened today at $0.38, close to its 52-week low of $0.35.
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -11.3% and a 38.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Onconova Therapeutics is Moderate Buy and the average price target is $5.25, representing a 1287.1% upside.
In a report issued on May 2, Maxim Group also upgraded the stock to Buy with a $3 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.83 and a one-year low of $0.35. Currently, Onconova Therapeutics has an average volume of 663.1K.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ONTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer.
